Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Retained Earnings (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Retained Earnings for 5 consecutive years, with -$351.4 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 16345.95% to -$351.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$351.4 million through Dec 2025, down 16345.95% year-over-year, with the annual reading at -$351.4 million for FY2025, 16345.95% down from the prior year.
  • Retained Earnings for Q4 2025 was -$351.4 million at Janux Therapeutics, down from $4.6 million in the prior quarter.
  • The five-year high for Retained Earnings was $4.6 million in Q3 2025, with the low at -$351.4 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$61.1 million, with a median of -$1.9 million recorded in 2022.
  • The sharpest move saw Retained Earnings tumbled 40814.81% in 2022, then surged 816.79% in 2025.
  • Over 5 years, Retained Earnings stood at -$270000.0 in 2021, then crashed by 40814.81% to -$110.5 million in 2022, then skyrocketed by 100.6% to $665000.0 in 2023, then soared by 225.26% to $2.2 million in 2024, then tumbled by 16345.95% to -$351.4 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$351.4 million, $4.6 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.